PURPOSE: Targeted delivery of radionuclides for diagnostic and therapeutic applications has until recently largely been limited to receptor ligands, antibodies and antibody-derived molecules. Here, we present a new type of molecule, a 15-kDa bivalent affibody called (Z(HER2:4))(2), with potential for such applications. The (Z(HER2:4))(2) affibody showed high apparent affinity (K (D)=3 nM) towards the oncogene product HER-2 (also called p185/neu or c-erbB-2), which is often overexpressed in breast and ovarian cancers. The purpose of this study was to investigate the in vivo properties of the new targeting agent. METHODS: The biodistribution and tumour uptake of the radioiodinated (Z(HER2:4))(2) affibody was studied in nude mice carrying tumours from xenografted HER-2 overexpressing SKOV-3 cells. RESULTS: The radioiodinated (Z(HER2:4))(2) affibody was primarily excreted through the kidneys, and significant amounts of radioactivity were specifically targeted to the tumours. The blood-borne radioactivity was, at all times, mainly in the macromolecular fraction. A tumour-to-blood ratio of about 10:1 was obtained 8 h post injection, and the tumours could be easily visualised with a gamma camera at this time point. CONCLUSION: The results indicate that the (Z(HER2:4))(2) affibody is an interesting candidate for applications in nuclear medicine, such as radionuclide-based tumour imaging and therapy.
PURPOSE: Targeted delivery of radionuclides for diagnostic and therapeutic applications has until recently largely been limited to receptor ligands, antibodies and antibody-derived molecules. Here, we present a new type of molecule, a 15-kDa bivalent affibody called (Z(HER2:4))(2), with potential for such applications. The (Z(HER2:4))(2) affibody showed high apparent affinity (K (D)=3 nM) towards the oncogene product HER-2 (also called p185/neu or c-erbB-2), which is often overexpressed in breast and ovarian cancers. The purpose of this study was to investigate the in vivo properties of the new targeting agent. METHODS: The biodistribution and tumour uptake of the radioiodinated (Z(HER2:4))(2) affibody was studied in nude mice carrying tumours from xenografted HER-2 overexpressing SKOV-3 cells. RESULTS: The radioiodinated (Z(HER2:4))(2) affibody was primarily excreted through the kidneys, and significant amounts of radioactivity were specifically targeted to the tumours. The blood-borne radioactivity was, at all times, mainly in the macromolecular fraction. A tumour-to-blood ratio of about 10:1 was obtained 8 h post injection, and the tumours could be easily visualised with a gamma camera at this time point. CONCLUSION: The results indicate that the (Z(HER2:4))(2) affibody is an interesting candidate for applications in nuclear medicine, such as radionuclide-based tumour imaging and therapy.
Authors: R Schier; J D Marks; E J Wolf; G Apell; C Wong; J E McCartney; M A Bookman; J S Huston; L L Houston; L M Weiner Journal: Immunotechnology Date: 1995-05
Authors: P L Beaumier; K A Krohn; J A Carrasquillo; J Eary; I Hellström; K E Hellström; W B Nelp; S M Larson Journal: J Nucl Med Date: 1985-10 Impact factor: 10.057
Authors: L B Shih; S R Thorpe; G L Griffiths; H Diril; G L Ong; H J Hansen; D M Goldenberg; M J Mattes Journal: J Nucl Med Date: 1994-05 Impact factor: 10.057
Authors: A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks Journal: Cancer Res Date: 1990-07-01 Impact factor: 12.701
Authors: S Rahima Benhabbour; J Christopher Luft; Dongwook Kim; Anekant Jain; Saurabh Wadhwa; Matthew C Parrott; Rihe Liu; Joseph M DeSimone; Russell J Mumper Journal: J Control Release Date: 2011-10-20 Impact factor: 9.776
Authors: Zheng Miao; Gang Ren; Lei Jiang; Hongguang Liu; Jack M Webster; Rong Zhang; Mohammad Namavari; Sanjiv S Gambhir; Faisal Syud; Zhen Cheng Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-15 Impact factor: 9.236
Authors: Zhen Cheng; Omayra Padilla De Jesus; Daniel J Kramer; Abhijit De; Jack M Webster; Olivier Gheysens; Jelena Levi; Mohammad Namavari; Sen Wang; Jinha Mark Park; Rong Zhang; Hongguang Liu; Brian Lee; Faisal A Syud; Sanjiv Sam Gambhir Journal: Mol Imaging Biol Date: 2009-09-25 Impact factor: 3.488
Authors: Torun Engfeldt; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsen; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev Journal: Eur J Nucl Med Mol Imaging Date: 2007-06-13 Impact factor: 9.236